{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 61,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 18,
  "notes": "The table displays clinical safety data for NXC-201, specifically focusing on Cytokine Release Syndrome and Immune cell associated Neurotoxicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/35",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note. No Grade 4 CRS with NXC-201. Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17987646-276d-42a0-9561-fd942a0d2e21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "table",
      "text": "Adverse event data table comparing NXC-201 dosages (150x10^6, 450x10^6, 800x10^6) across CRS, ICANS, and toxicity management metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49854641-92af-4dbe-bd99-1693ee61b256",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Adverse Event Profile – NXC-201",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11d21a43-9b1c-4b03-b882-e39cb39654bf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "dc388dd4-f9fb-4965-83d8-efae77baf89f",
      "evidence": "table/data: Adverse event data table comparing NXC-201 dosages (150x10^6, 450x10^6, 800x10^6) across CRS, ICANS, and toxicity management metrics.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 61,
      "from": 18,
      "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}